JAK Inhibitors Don’t Increase Clot Risk in Patients With Inflammatory Skin Disease
Use of JAK inhibitors was not associated with a higher risk of all-cause mortality, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) compared to other agents in patients with inflammatory skin diseases. JAK inhibitors have a well-documented record of effectiveness against dermatological conditions, such as psoriasis, atopic dermatitis, alopecia areata, and vitiligo.